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To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus
on speciﬁc issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11–12
May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in
each of four areas: pathology and molecular biomarkers, ﬁrst-line/second and further lines of treatment in advanced
disease, early-stage disease and locally advanced disease. For each question, recommendations were made including
reference to the grade of recommendation and level of evidence. This consensus paper focuses on ﬁrst line/second and
further lines of treatment in advanced disease.
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background
In 2009, ESMO decided to complement the ESMO Clinical
Practice Guidelines (CPGs) with further recommendations from
‘Consensus Conferences’. For lung cancer, the ﬁrst meeting of
this kind was held in Lugano in 2010, which resulted in the pub-
lication of two consensus manuscripts [1, 2].
The 2nd meeting, held in Lugano in May 2013, followed the
same format as the ﬁrst edition. Four working groups were
appointed, each with 8–10 participants from several disciplines
and led by a chair. A total of 35 experts were involved in this
consensus process (see Panel Members listed in the Appendix).
The four speciﬁc areas were:
• NSCLC pathology and molecular biomarkers,
• First line, second line and further lines of treatment in
advanced NSCLC,
• Early-stage NSCLC (stages I–II),
• Locally advanced NSCLC (stage III).
Before the conference, each working group identiﬁed a
number of clinically relevant questions suitable for consensus
discussion and provided the available literature. At the confer-
ence, in parallel sessions, each group discussed and reached
agreement on the questions previously chosen. Decisions were
made using studies published in peer review journals. The con-
sideration of abstracts was at the discretion of the groups. All
relevant scientiﬁc literature, as identiﬁed by the experts, was
considered. A systematic literature search was not carried out.
The recommendations from each group were then presented
to the full panel of experts and discussed, and a general consen-
sus was reached. The Infectious Diseases Society of America
grading system was used to assign levels of evidence and grades
of recommendation [3].
The consensus ﬁndings of the group on ﬁrst line/second and
further lines of treatment in advanced disease—approved by the
Consensus Conference panel of experts—is reported here.
introduction
Around 70% of NSCLC patients are diagnosed with advanced
disease at diagnosis. The majority of patients diagnosed with
NSCLC are unsuitable for curative treatment. Molecular character-
isation has led to the deﬁnition of new subgroups, e.g. epidermal†See Appendix for Panel Members.
*Correspondence to: ESMO Guidelines Working Group, ESMO Head Ofﬁce, Via L.
Taddei 4, CH-6962 Viganello-Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org
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growth factor receptor (EGFR)-mutated NSCLC, anaplastic
lymphoma kinase (ALK)-rearranged NSCLC that need speciﬁc
treatments and strategies and are thus discussed here in speciﬁc
sections. The ‘all comers’ section concerns all advanced NSCLC
patients, whatever the tumour mutational proﬁle, while tumours
of patients without any known driver mutation are speciﬁcally
addressed by the panel.
NSCLC all comers
should we start ﬁrst-line chemotherapy in
asymptomatic patients with advanced NSCLC at
diagnosis or at occurrence of symptoms?
The survival beneﬁt achieved by palliative chemotherapy in
asymptomatic patients with metastatic NSCLC is of the same rela-
tive magnitude as in symptomatic ones [4]. Furthermore, quality
of life (QoL) was either no worse or improved for those patients
receiving chemotherapy in eight clinical trials, four with plat-
inum-based and four with single-agent third-generation drugs [5].
Although not less effective, delaying palliative chemotherapy until
symptomatic progression may result in shorter time to progres-
sion, worsening of QOL and less drug exposure, all of which are
potentially detrimental to outcome [6].
Recommendation 1: the administration of ﬁrst-line chemother-
apy should be offered at diagnosis to asymptomatic patients
with metastatic NSCLC.
Strength of recommendation: B
Level of evidence: III
should we use cisplatin or carboplatin-based
chemotherapy?
Concerns about the toxic effects associated with cisplatin-based
chemotherapy and the availability of platinum analogues with
fewer side-effects have led to a number of randomised trials in
metastatic NSCLC patients. Two meta-analyses have been pub-
lished that address this issue [7, 8]. Hotta et al. [7] analysed
eight trials and reported a higher response rate (RR) for cisplatin
compared with carboplatin treatment with no survival differ-
ence. Subgroup analyses revealed that patients treated with a
third-generation compound in conjunction with carboplatin
had a shorter survival than those receiving cisplatin plus the
same agents [hazard ratio (HR) 1.106, 95% conﬁdence interval
(CI) 1.005–1.218; P = 0.039]. This survival advantage was
obtained at the cost of a higher but not statistically signiﬁcant
difference in terms of lethal toxic effects. In a more recent meta-
analysis using individual patient data, Ardizzoni et al. [8]
observed a signiﬁcant increase in response for the cisplatin-
treated patients, with no signiﬁcant survival difference. In a pre-
speciﬁed analysis, the authors found an interaction between
histology and the use of third-generation agents; patients with
non-squamous tumours fared better when treated with cis-
platin-based chemotherapy. Furthermore, once again, patients
treated with third-generation compounds in conjunction with
cisplatin had a longer survival when compared with those
treated with carboplatin plus the same agent. The results were
similar to the Hotta et al. [7] analysis with regard to toxic
effects. Cisplatin has been evaluated at a dose of at least 75 mg/
m2 in most of the pivotal studies with third-generation com-
pounds [9, 10].
Recommendation 2: cisplatin should be used in ﬁt patients with
performance status (PS) 0–1 who have adequate organ function.
Strength of recommendation: B
Level of evidence: I
Recommendation 3: cisplatin at 75 mg/m2 q3wks should be
used with third-generation drugs.
Strength of recommendation: B
Level of evidence: V
is there a single platinum-based doublet standard
chemotherapy in squamous and non-squamous
NSCLC?
Randomised studies that have compared platinum-based doublets
including third-generation drugs (vinorelbine, gemcitabine,
taxanes) among themselves [10–12] did not show any differences
in survival and gave no evidence for a single ‘standard’ doublet
for the treatment of metastatic NSCLC. The observation that doc-
etaxel/cisplatin was superior to vinorelbine/cisplatin in a rando-
mised study [12] has not been conﬁrmed elsewhere. A phase III
randomised trial comparing cisplatin/pemetrexed versus cis-
platin/gemcitabine showed no difference in outcome between the
two combinations with a lower haematological toxicity proﬁle for
the pemetrexed-based regimen [10]. A pre-planned subgroup
analysis showed a survival advantage for cisplatin/pemetrexed
when compared with cisplatin/gemcitabine in non-squamous
histology (11.8 versus 10.4 months, respectively; HR 0.81, 95% CI
0.70–0.94; P = 0.005), while a survival advantage for the gemcita-
bine-based combination was observed in squamous histology. No
prospective conﬁrmatory trials have been carried out. To date, no
comparative data of cisplatin/pemetrexed versus other platinum-
based doublets are available.
Recommendation 4: there is no single platinum-based doublet
standard chemotherapy.
Pemetrexed-based doublets are restricted to non-squamous
NSCLC.
Strength of recommendation: A
Level of evidence: I
howmany cycles of platinum-based
chemotherapy?
Two randomised phase III trials compared three versus six
cycles of chemotherapy with cisplatin/vinblastine/mitomycin C,
and carboplatin/vinorelbine, respectively [13, 14]. Both trials
reported no signiﬁcant differences in any of the outcomes,
except increased toxicity for the more prolonged treatment.
However, these two trials were underpowered and considered
inconclusive. Only one randomised phase III trial formally com-
pared four with six cycles of a third-generation regimen in
Asian patients who were non-progressing after two cycles [15].
There was a beneﬁt in time to progression (TTP) with six cycles
compared with four cycles (HR 0.63, 95% CI 0.50–0.80,
P = 0.001), but this did not translate into survival beneﬁt (HR
1.11, 95% CI 0.83–1.51, P = 461). Lima’s systematic review and
meta-analysis indicated that more than four cycles was
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associated with a longer progression-free survival (PFS) (HR
0.75, 95% CI 0.60–0.85; P < 0.0001) and a non-statistically sign-
iﬁcant decrease in mortality (HR 0.97, 95% CI 0.84–1.11;
P = 0.65) but with increased haematological toxicity [16]. Soon
et al. found in analysis of 13 randomised, controlled trials (3027
patients) that PFS was increased (HR 0.75, 95% CI 0.69–0.81;
P < 0.00001) with a small increase in survival (HR 0.92, 95% CI
0.86–0.99; P = 0.03) [17].
Recommendation 5: four cycles of chemotherapy is standard.
Strength of recommendation: A
Level of evidence: I
Recommendation 6: continuation of a doublet regimen beyond
4 cycles may be considered in selected, non-progressing patients
Strength of recommendation: C
Level of evidence: I
is there any indication for an anti-angiogenic
treatment in NSCLC?
A meta-analysis showed superiority of platinum-based chemo-
therapy plus bevacizumab (an anti-VEGF antibody), when com-
pared with chemotherapy alone [18]. Studies were conducted in
chemotherapy-naive patients with stage IIIB/IV non-squamous
NSCLC and PS of 0–1; due to safety concerns, patients with brain
metastases, gross haemoptysis and those receiving therapeutic
anticoagulation were excluded. In the ECOG 4599 study, bevaci-
zumab/carboplatin/paclitaxel versus carboplatin/paclitaxel was
evaluated [19]. Overall survival (OS) was signiﬁcantly longer in
patients receiving combined treatment than in those receiving
chemotherapy alone (median survival: 12.3 versus 10.3 months;
HR 0.79, 95% CI 0.67–0.92; P = 0.003). Median PFS times in the
two groups were 6.2 and 4.5 months, respectively (HR 0.66, 95%
CI 0.57–0.77; P < 0.001), with corresponding RRs of 35% and
15% (P < 0.001). A second phase III trial, enrolling outside the
United States, has evaluated the combination of bevacizumab (15
or 7.5 mg/kg every 3 weeks until disease progression) with gemci-
tabine/cisplatin versus gemcitabine/cisplatin plus placebo [20].
The primary end point was PFS. This trial was not powered to
compare the two doses of bevacizumab directly. The PFS was
signiﬁcantly longer in patients receiving chemotherapy plus beva-
cizumab than in those receiving chemotherapy plus placebo
[placebo arm: median PFS 6.1 months; 7.5 mg/kg bevacizumab
arm: median PFS 6.7 months (HR 0.75, 95% CI 0.64–0.87;
P = 0.0003); 15 mg/kg bevacizumab arm: median PFS 6.5 months
(HR 0.85, 95% CI 0.73–1.00; P = 0.045)]. In this trial, there was
no survival beneﬁt for patients receiving bevacizumab versus
placebo [21]. Two doses of bevacizumab may be delivered (7.5 or
15 mg/kg). After failure of a platinum-based chemotherapy, the
beneﬁt of bevacizumab has not been demonstrated so far [22].
Tyrosine kinase inhibitors (TKIs) of vascular endothelial growth
factor receptor do not increase the efﬁcacy of platinum-based
chemotherapy. Some efﬁcacy has been demonstrated when
combined to a second-line therapy but none of these agents is
currently approved in this setting [23].
Recommendation 7: when platinum-based chemotherapy is
indicated, a combination with bevacizumab is a treatment
option in eligible patients with non-squamous NSCLC.
In this case, carboplatin/paclitaxel is the preferred combination.
Strength of recommendation: I
Level of evidence: A
should we offer switch maintenance treatment and,
if yes, to which patients?
Two phase III randomised trials addressed the issue of ‘switch
maintenance’ therapy with pemetrexed or erlotinib after four
cycles of platinum-based chemotherapy [24, 25]. Both trials
reported PFS and OS advantages for maintenance therapy
(pemetrexed or erlotinib) versus placebo. In the pemetrexed
study, OS for non-squamous histology was 15.5 versus 10.3
months in the pemetrexed and the placebo arms, respectively
(HR 0.70, 95% CI 0.56–0.88; P = 0.002). In the erlotinib versus
placebo study, a survival advantage was observed (median sur-
vival of 12 versus 11 months, HR 0.81, 95% CI 0.70–0.95;
P = 0.0088) [25].
Subgroup analyses showed a greater beneﬁt for erlotinib in patients
with stable disease after induction chemotherapy. Unfortunately,
neither trial addressed the question of ‘early second-line’ (or
‘switch maintenance’) versus common second-line treatment
started at disease progression.
Recommendation 8: switch maintenance with pemetrexed may
be offered to patients with advanced non-squamous carcinoma
(EGFR wild type [WT]) who are not treated with pemetrexed
ﬁrst-line treatment.
Strength of recommendation: B
Level of evidence: II
Recommendation 9: switch maintenance with erlotinib is a
treatment option for patients with advanced NSCLC who have
stable disease after ﬁrst-line platin-based chemotherapy.
Strength of recommendation: B
Level of evidence: IV
should we offer ‘continuation’ maintenance
treatment and, if yes, to which patients?
The PARAMOUNT phase III trial randomised 539 patients
with advanced non-squamous NSCLC who did not progress on
induction cisplatin–pemetrexed to either maintenance peme-
trexed or best supportive care (BSC). Both PFS (HR 0.64, 95%
CI 0.51–0.81) and OS (HR 0.78, 95% CI 0.64–0.96) improved
signiﬁcantly (P = 0.0002 and P = 0.0195, respectively) in the
pemetrexed maintenance treated patients [26]. There are no
other trials available with adequate power to detect PFS or OS
differences that tested the continuation maintenance concept.
Recommendation 10: continuation maintenance treatment
with pemetrexed may be offered to patients with advanced
non-squamous NSCLC not progressing after ﬁrst-line peme-
trexed-cisplatin therapy.
Strength of recommendation: A
Level of evidence: I
which chemotherapy for elderly patients?
More than 50% of NSCLCs are diagnosed in patients aged >65
years with 30% being in patients >70 years. Elderly patients
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are under-represented in clinical trials [27], but two main ran-
domised phase III trials showed single-agent chemotherapy
with third-generation agents as the standard of care for ﬁrst-line
therapy for clinically unselected elderly advanced NSCLC
patients [5, 28]. However, retrospective analyses from large
phase III randomised trials showed similar efﬁcacy and tolerabil-
ity when elderly and adult patients were compared. This issue
has recently been addressed in a prospective randomised trial
comparing monthly carboplatin plus weekly paclitaxel versus
single-agent vinorelbine or gemcitabine, reporting an increased
RR and a survival advantage for combination therapy but with
increased toxicity (neutropenia and febrile neutropenia) [29].
Platinum-based chemotherapy may therefore be the preferred
option for elderly patients with PS 0–1 and adequate organ
function, while single agent is recommended for unﬁt patients.
Recommendation 11: platinum-based chemotherapy is pre-
ferred in ﬁt elderly patients with PS 0–1 and adequate organ
function.
Single-agent third-generation drugs are preferred in unﬁt
elderly patients.
Strength of recommendation: B
Level of evidence: I
should we re-challenge with platinum compounds
and, if yes, when and in which patients?
Two identical design phase II trials randomised advanced
NSCLC patients who progressed on ﬁrst-line cisplatin-based
chemotherapy to either pemetrexed monotherapy or the com-
bination of carboplatin and pemetrexed [30, 31]. While neither
of the trials was adequately powered to detect a survival differ-
ence, in the pooled analysis comprising 479 patients, there was
no difference in OS (HR 0.90, 95% CI 0.74–1.10, P = 0.316). No
other randomised trials are available that investigate the role of
re-challenge with platinum compounds.
Recommendation 12: in advanced NSCLC patients treated
with ﬁrst-line cisplatin-doublet chemotherapy, there is no
proven role for re-challenge with platinum compounds.
Strength of recommendation: D
Level of evidence: II
is there any indication for systemic treatment
beyond second line?
In second and third line, erlotinib increases the OS by 2 months
compared with placebo [32]. Systemic treatment can be safely
administrated beyond second line. Sorafenib has been safely
tested in third or fourth line compared with placebo in a rando-
mised trial [33]. In a retrospective analysis of 613 consecutive
patients receiving ﬁrst-line therapy [34], 173 received a third
line with chemotherapy (131) or a TKI (42). PS was improved in
52% and symptom relief was achieved in 92% (121 of 131 with
symptoms). Predictors of the likelihood of beneﬁting from
third-line therapy were: disease control to ﬁrst- and second-line
therapy (HR 0.47, 95% CI 0.33–0.67, P = 0.001), age <70 (HR
0.73, 95% CI 0.53–0.99, P = 0.047), smoking <10 pack-years
(HR 0.82, 95% CI 0.57–0.93, P = 0.036), lack of symptoms (HR
0.75, 95% CI 0.61–0.92, P = 0.007), <5 kg weight loss since start
of second-line therapy (HR 0.63, 95% CI 0.52–0.75, P = 0.013)
and no extra-thoracic spread at the initiation of the third-line
treatment (HR 0.67, 95% CI 0.47–0.94, P = 0.042).
Recommendation 13: selected patients may beneﬁt from third-
line or fourth-line systemic treatment.
Strength of recommendation: C
Level of evidence: II
is there an optimal time and systemic treatment for
bone metastasis?
Given the incidence of bone metastases in NSCLC (30%–40% of
patients with NSCLC develop bone metastases), it may be rea-
sonable to evaluate for bone disease upon disease diagnosis.
Zoledronic acid (ZA) (4 mg Q4W) reduces skeletal-related
events (pathologic fracture, radiation to or surgery of bone or
spinal cord compression) [35]. In a subset analysis of a phase III
trial, comparing denosumab (120 mg Q4W) with ZA in the
treatment of bone metastases from solid tumours, denosumab
was associated with improved median OS versus ZA in 702
patients with NSCLC (9.5 versus 8.0 months; HR 0.78; P = 0.01)
[36]. Treatment with either agent should be continued for as
long as it is practically feasible in the absence of any signiﬁcant
adverse effects.
Recommendation 14: systemic treatment may be offered upon
diagnosis of bone metastases and may be continued for as long as
it is practically feasible, in the absence of any signiﬁcant adverse
effects. Denosumab and zoledronic acid are valid options.
Strength of recommendation: B
Level of evidence: II
NSCLCwithout driver mutations (i.e.
mutation of EGFR or ALK rearrangement)
should platinum-based chemotherapy be offered to
PS 2 patients?
On the basis of current evidence, chemotherapy appears
justiﬁed in patients with advanced NSCLC and a PS of 2 [37].
Subgroup analyses from several randomised trials suggest that
several new-generation cytotoxic drugs are superior to BSC
alone in this category of patients. Single-agent chemotherapy
with these drugs (e.g. gemcitabine, vinorelbine and taxanes)
represents a signiﬁcant option for palliative treatment of these
patients. Taking into account the superiority shown by the car-
boplatin/paclitaxel combination compared with paclitaxel alone
in a subgroup analysis of PS 2 patients, and the efﬁcacy and the
tolerability shown by carboplatin-based doublets in three rando-
mised phase III trials, platinum-based combinations are the pre-
ferred option for these patients [29, 38–40].
Recommendation 15: platin-based combinations are preferred
over single-agent chemotherapy.
Strength of recommendation: B
Level of evidence: I
which patients should receive second- or third-line
therapy?
In patients without EGFR mutations who have received prior
chemotherapy, second- and third-line treatment might be
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beneﬁcial, when there are signs of both clinical and/or radio-
logical progression. Various studies have reported RRs of 10% and
some improvement in disease-related symptoms. Combination
therapies did not show any advantage over single-agent treatment.
In general, only an improvement in PFS is reported. Three phase
III studies showed that in patients with a good performance status
(PS 0–1): (i) docetaxel increases the OS by 9 weeks compared with
BSC at the cost of some toxicity [41]; (ii) pemetrexed is as effective
as docetaxel with fewer side-effects [42]; (iii) erlotinib increases the
OS by 2 months compared with placebo [32].
The comparison of erlotinib with chemotherapy has only been
addressed in patients who progressed during ﬁrst-line therapy
with no differences in PFS or OS [43]. Geﬁtinib was considered to
be slightly superior to docetaxel in an Asian population with a
high percentage of non-smokers and adenocarcinoma, but did
not show an improvement in OS or QoL [44].
Recommendation 16: second- or third-line therapy should be
offered to patients with PS 0–1 who present with signs of
disease progression (radiological and/or clinical) after ﬁrst- or
second-line therapy.
Strength of recommendation: A
Level of evidence: I
what kind of treatment should be offered
in second line?
Several agents have been registered for use in second-line (see
above). The choice of therapy depends on the ﬁrst-line treat-
ment, co-morbidities and disease-free period [32, 41, 42, 45]. In
third line, only erlotinib is registered for those who are EGFR
TKI-naïve [32]. With every increase in line of therapy the RR
and OS decrease. In ﬁt patients, supportive care and inclusion in
clinical studies should be offered.
Recommendation 17: chemotherapy can be offered to patients who
have a PS 0–1. Regardless of the WT status of the tumour a choice
between docetaxel, pemetrexed or erlotinib can be made. For ﬁt
patients, chemotherapy may be more effective than erlotinib.
Strength of recommendation: B
Level of evidence: I
EGFR-mutated NSCLC
what is the preferred ﬁrst-line treatment?
Gain-of-function mutations in the tyrosine kinase domain of the
EGFR gene markedly increase sensitivity to EGFR TKIs. The most
common oncogenic mutations are deletion in exon 19 (45%–50%
of all somatic EGFR mutations) and a point mutation (L858R) in
exon 21 (35%–45% of mutations) [46]. These mutations are pre-
dictive of clinical activity of the EGFR TKIs, which yield a superior
RR and PFS as well as better QoL scores when compared with
combination chemotherapy in the ﬁrst-line setting, as demon-
strated in several randomised trials [47–51].
Recommendation 18: an EGFR TKI is the preferred ﬁrst-line
treatment in patients with EGFR-mutated NSCLC
Strength of recommendation: A
Level of evidence: I
what is the optimal management of brain
metastases at diagnosis?
During the course of the disease, 20%–30% of patients with
metastatic NSCLC will develop brain metastases [46–48]. A pro-
spective phase II non-randomised trial demonstrated the safety
of combining an EGFR TKI with whole-brain radiation therapy
(WBRT). In that study, erlotinib was well-tolerated in combin-
ation with WBRT. Median survival time was 9.3 months for
those with wild-type EGFR and 19.1 months for those with
EGFRmutations, with a favourable objective RR (ORR) [52].
Recommendation 19: patients with EGFR-mutated NSCLC
and with brain metastases may be considered for treatment
with an EGFR TKI. Radiotherapy can safely be given concomi-
tantly to EGFR TKI.
Strength of recommendation: C
Level of evidence: V
what kind of treatment should be offered
in second line?
In patients with EGFR mutations who had not previously
received an EGFR TKI, second-line treatment with EGFR TKI
has shown comparable efﬁcacy compared with ﬁrst-line treat-
ment with an EGFR TKI [49] and a signiﬁcant improvement of
RR as well as PFS compared with chemotherapy [53, 54].
Recommendation 20: the use of an EGFR TKI in second line is
recommended if not received previously in patients with
EGFR-mutated NSCLC.
Strength of recommendation: A
Level of evidence: I
In patients with EGFR mutations who had received prior treat-
ment with an EGFR TKI, second-line treatment with platinum-
based chemotherapy improved OS [47–51]. However, the deci-
sion about the appropriate time to change treatment should be
made carefully because relevant impact on OS has been
observed with treatment beyond progression with EGFR TKI in
slowly progressing tumours [55]. Furthermore, an overlap of
EGFR TKI and chemotherapy could be considered due to the
risk of ﬂare following abrupt discontinuation of EGFR TKI [56].
Recommendation 21: the use of platinum-based chemotherapy
is recommended if the patient with EGFR-mutated NSCLC has
received ﬁrst-line treatment with an EGFR TKI.
Strength of recommendation: A
Level of evidence: I
what kind of treatment should be offered
in third line?
Retrospective case series with limited numbers of patients have
shown that re-exposure to an EGFR TKI after prior treatment
with EGFR TKI and chemotherapy may have an impact on
tumour response and PFS [57]. In a randomised phase III trial,
which investigated afatinib versus placebo, pre-treatment with
an EGFR TKI and chemotherapy failed to demonstrate a signiﬁ-
cant improvement of OS but revealed a signiﬁcant improvement
of RR and PFS in favour of afatinib [58].
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Recommendation 22: in patients with EGFR-mutated NSCLC
who had already been treated with an EGFR TKI and chemo-
therapy, consider further EGFR TKIs as an option.
Strength of recommendation: C
Level of evidence: V
ALK-rearranged NSCLC
what is the preferred ﬁrst-line treatment?
The ALK inhibitor crizotinib has been evaluated in second line
and beyond [59]. No randomised trial has presented data of its
activity in ﬁrst line compared with a platinum-based therapy;
therefore, the use of platinum-based chemotherapy should be
preferred in this setting in ﬁt patients. Crizotinib may, however,
be an option for patients who are not suitable candidates for
chemotherapy. A subgroup analysis of a prospective study has
shown a superior activity of pemetrexed compared with doce-
taxel [59]. The roles of bevacizumab and of maintenance
therapy have not been studied in this speciﬁc subgroup.
Recommendation 23: platinum-based chemotherapy should be
used in ﬁt patients with ALK-rearranged NSCLC. In combin-
ation with platinum agents, pemetrexed is to be preferred over
docetaxel.
Strength of recommendation: C
Level of evidence: II
what kind of treatment should be offered
in second line?
A large open-label phase III trial compared oral treatment with
crizotinib (250 mg, twice daily) with intravenous chemotherapy
(either pemetrexed 500 mg/m2 or docetaxel 75 mg/m2) in 347
patients with locally advanced or metastatic ALK-positive
NSCLC who had received one prior platinum-based regimen
[59]. Patients in the chemotherapy group who had disease pro-
gression were permitted to cross-over to crizotinib. Median PFS
was 7.7 months in the crizotinib group versus 3.0 months in the
chemotherapy group (HR for progression or death with crizoti-
nib, 0.49; 95% CI 0.37–0.64; P < 0.001). However, an interim
analysis of OS showed no signiﬁcant improvement with crizoti-
nib (HR for death in the crizotinib group, 1.02; 95% CI 0.68–
1.54; P = 0.54). Finally, greater reductions in symptoms of lung
cancer and greater improvement in global QoL were recorded
with crizotinib than with chemotherapy.
Recommendation 24: crizotinib is the standard of treatment in
crizotinib-naïve ALK-rearranged NSCLC patients who have
received one prior platinum-based regimen.
Strength of recommendation: A
Level of evidence: I
what kind of treatment should be offered
in third line?
No prospective clinical trial data exist. Having received a plat-
inum-based regimen in the ﬁrst line and crizotinib in the
second, these patients are expected to receive monotherapy
pemetrexed, docetaxel or erlotinib. Retrospective analysis from
the PROFILE 1005 trial suggests that pemetrexed (single-agent
or combination) may be effective in ALK-positive NSCLC.
Although pemetrexed ORR and TTP in the ﬁrst-line setting
from PROFILE 1005 concur with those in landmark trials evalu-
ating unselected NSCLC populations; there is, however, a ten-
dency for a higher ORR and improved PFS or TTP with second-
line pemetrexed-based regimens than in the unselected popula-
tions [59]. Since the majority of ALK-positive patients are of
adenocarcinoma histological classiﬁcation, pemetrexed may be
offered for patients that were not exposed to pemetrexed previ-
ously. Active second-generation ALK inhibitors are under inves-
tigation and may lead to modiﬁcation of this statement in the
near future.
Recommendation 25: in third line, pemetrexed may be offered
for ALK-rearranged NSCLC patients who were not previously
exposed to pemetrexed.
Strength of recommendation: C
Level of evidence: V
emerging biomarkers and secondary
resistance
dowe need to re-biopsy a patient on disease
progression after a targeted treatment for a tumour
with a targetable genomic driving alteration
(i.e. EGFR mutation)?
Several groups have reported on the molecular ﬁndings in biop-
sies taken at the time of disease progression in patients treated
with inhibitors of activating mutations or translocations, par-
ticularly erlotinib or geﬁtinib and crizotinib. Consequently, rele-
vant information is available on the most frequent mechanisms
of resistance for EGFR inhibitors (T790M mutation, and less
frequently Met ampliﬁcation or HGF over-expression, small-cell
transformation and others) or crizotinib (ALK mutation, ALK
ampliﬁcation and others such as EGFR mutation) [60–64].
However, only in very few circumstances (e.g. small-cell lung
cancer [SCLC] transformation), does the information obtained
after re-biopsy guide treatment decisions in clinical practice at
this time.
Recommendation 26: on disease progression after a targeted
treatment for a tumour with a targetable genomic driving al-
teration (i.e. EGFR mutation), re-biopsy is not mandatory. As
some patients may derive beneﬁt in terms of therapeutic guid-
ance from genotyping and/or phenotyping at the time of
disease progression (e.g. transformation to SCLC, inclusion in
a speciﬁc clinical trial, etc.), beneﬁts and risks of this approach
are to be discussed with the patient.
Strength of recommendation: C
Level of evidence: III
how should oligometastatic progression during
TKI be managed?
Local therapies including radiation, radiofrequency ablation
and metastasectomy are established treatment strategies in
certain cancers including renal cell carcinoma, sarcoma and
colorectal cancer. Several experiences also support the use of
local therapies (surgery, stereotactic radiation) with continued
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EGFR or ALK inhibition in cases of oligometastatic progres-
sion, resulting in minimal toxicity and in months to years of
disease control [65].
Before proceeding with local therapy, patients should have a
full evaluation of the extent of disease, including CNS imaging.
Recommendation 27: in case of oligometastatic progression
during TKI treatment, use a local treatment (such as surgery
or radiotherapy) and continue/resume TKI.
Strength of recommendation: C
Level of evidence: V
what is the optimal treatment for patients with
ROS1, RET, BRAF or HER2 genomic alterations
after standard treatment?
Beyond the most common driver genomic alterations with amen-
able speciﬁc therapies (EGFR mutation and ALK translocation),
there are a number of other low prevalence (<2%) potentially ac-
tionable mutations (e.g. BRAF, HER2, etc.) or translocations
(ROS1, RET etc.) identiﬁable in lung cancers [66]. Pre-clinical
data with speciﬁc inhibitors of these targets are encouraging but
clinical data are limited so far. Small phase II trials have shown
encouraging RRs with dabrafenib (60% RR in 20 patients with
BRAF V600E mutated NSCLC) [67], and crizotinib (56% RR in
30 patients with ROS1 translocated NSCLC). Trastuzumab and
dacomitinib have shown signs of activity in HER2-mutated
NSCLC [68]. RET inhibitors are effective growth inhibitors but
clinical experiences are limited to isolated cases. At present,
testing for these genomic alterations, if feasible, may identify ap-
propriate candidates for clinical trials or off-label treatment with
speciﬁc inhibitors, once standard therapies have been used and
patients understand and accept the limited evidence available and
potential risks.
Recommendation 28: speciﬁc targeted treatments (e.g. crizoti-
nib, vandetanib, dabrafenib, trastuzumab) should be discussed
with the patient and may be considered in individual patients
based on expected risk-beneﬁt, biological plausibility, pre-clin-
ical data and limited clinical efﬁcacy data for authorised ther-
apies in different indications.
Strength of recommendation: C
Level of evidence: V except ROS1 (III)
note
Levels of evidence and grades of recommendation have been
applied using the system shown in Table 1. Statements without
grading were considered justiﬁed standard clinical practice by
the experts and the ESMO faculty.
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